This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive talks with U.S. private equity company CD&R to sell a controlling stake in its...
AbbVie ABBV is set to report third-quarter earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.28 billion and $2.93 per share, respectively.The...
Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding following a report from Reuters on opposition from several large pharma companies as...
/CNW/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it's...
Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the third quarter. Sales increased 6% year over year to CHF 15.1 billion and were up 9% at constant exchange rates (CER).Stay up-to-date...
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.
For Immediate ReleaseChicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
This week, Johnson & Johnson JNJ began the third-quarter earnings season for the drug and biotech sector. The FDA granted approval to a few new drugs, which included Pfizer’s PFE gene therapy for hemophilia,...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Each October, breast cancer awareness gains momentum through impactful campaigns and advancements in...
Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi.The drug is approved in combination with Pfizer’s Ibrance...